

ADD TP: Rs 270 | ▲ 7%

MAYUR UNIQUOTERS

Textiles

14 August 2020

Tepid quarter, upside limited; downgrade to ADD

Mayur Uniquoters' (MUNI) Q1FY21 volumes nosedived 74% YoY as the lockdown hit demand, leading to a standalone revenue decline of 70% and an operating margin loss of Rs 5mn. Management expects Q2 to post ~60% of normal sales and is hopeful of a return to pre-Covid levels in Q4FY21. We maintain estimates and roll forward to a Sep'21 TP of Rs 270 (from Rs 250). The ~22% rally in stock price since July caps upside potential – downgrade from BUY to ADD.

Arun Baid research@bobcaps.in

Revenue shrinks due to lockdown: MUNI reported a 70% YoY drop in standalone revenue to Rs 381mn owing to a 74% reduction in volumes. Revenue declined across segments as the lockdown sapped demand. Management expects QoQ improvement and is targeting ~60% of YoY revenues in Q2 followed by a return to normal levels in Q4. Revenues would be driven by the automotive segment in the near term as the footwear business still lags. MUNI has received approval to supply to Volkswagen India from Q3FY21. Supplies to Mercedes, South Africa, are expected to start from Q4FY21/Q1FY22.

Operating margins decline: MUNI reported a standalone EBITDA loss of Rs 5mn due to negative operating leverage as sales plummeted during the Covid-19 lockdown. However, it reported PBT of Rs 12mn primarily aided by higher other income (+50% YoY). The company expects margins to increase going ahead due to cost control initiatives and better sales.

Downgrade to ADD: MUNI's operational performance is likely to improve sequentially along with unlocking of the economy. We maintain estimates and roll over to a new Sep'21 TP of Rs 270 (earlier Rs 250), retaining our target one-year forward P/E of 15x. Downgrade from BUY to ADD on limited upside potential at current valuations of 15.3x FY22E EPS.

Licker/Price	MUNI IN/Rs 252
Market cap	US\$ 152.1mn
Shares o/s	45mn
3M ADV	US\$ 0.3mn
52wk high/low	Rs 305/Rs 119
Promoter/FPI/DII	61%/7%/31%
C NICE	

Source: NSE

STOCK PERFORMANCE



Source: NSE

KEY FINANCIALS

Y/E 31 Mar	FY19A	FY20P	FY21E	FY22E	FY23E
Total revenue (Rs mn)	5,913	5,280	3,685	5,617	6,261
EBITDA (Rs mn)	1,292	1,039	551	1,107	1,295
Adj. net profit (Rs mn)	727	798	328	744	871
Adj. EPS (Rs)	16.0	17.6	7.2	16.4	19.2
Adj. EPS growth (%)	(19.7)	9.8	(58.9)	127.2	17.0
Adj. ROAE (%)	15.0	14.6	5.6	11.9	12.8
Adj. P/E (x)	15.7	14.3	34.8	15.3	13.1
EV/EBITDA (x)	7.6	9.2	17.2	8.3	6.9



FIG 1 - CONSOLIDATED QUARTERLY PERFORMANCE

(Rs mn)	Q1FY21	Q1FY20	Y ₀ Y (%)	Q4FY20	Q ₀ Q (%)
Revenues	389	1,274	(69.4)	1,311	(70.3)
Raw material consumed	220	822	(73.2)	677	(67.5)
% of sales	57.8	64.1	(630bps)	48.5	928bps
Employee expense	80	84	(4.8)	93	(13.1)
% of sales	21.1	6.6	1,456bps	6.6	1,450bps
Other expense	103	193	(46.8)	216	(52.4)
% of sales	27.0	15.0	1,193bps	15.5	1,149bps
Total expenditure	403	1,099	(63.3)	985	(59.1)
EBITDA	(14)	174	(108.1)	326	(104.3)
% of sales	(3.6)	13.7	(1,729bps)	24.9	(2,847bps)
Depreciation	34	43	(21.4)	50	(32.6)
Other income	55	37	50.9	61	(9.5)
Interest cost	5	2	136.1	9	(41.6)
PBT	2	165	(98.6)	328	(99.3)
Taxes	1	68	(98.0)	80	(98.3)
Effective tax rate (%)	59.8	41.1	1,871bps	24.3	3,552bps
PAT	1	97	(99.0)	248	(99.6)


Source: Company, BOBCAPS Research

FIG 2 - STANDALONE QUARTERLY PERFORMANCE


(Rs mn)	Q1FY21	Q1FY20	Y ₀ Y (%)	Q4FY20	Q ₀ Q (%)
Revenues	381	1,282	(70.3)	1,394	(72.7)
Raw material consumed	217	790	(72.5)	760	(71.5)
% of sales	57.0	61.6	(462bps)	54.5	245bps
Employee expense	90	81	11.2	90	0.5
% of sales	23.8	6.3	1,741bps	6.4	1,731bps
Other expense	78	160	(51.2)	186	(58.1)
% of sales	20.5	12.4	801bps	13.3	713bps
Total expenditure	385	1,031	(62.6)	1,036	(62.8)
EBITDA	(5)	251	(101.8)	358	(101.3)
% of sales	(1.2)	19.6	(2,081bps)	25.7	(2,689bps)
Depreciation	34	43	(21.5)	50	(32.6)
Other income	55	37	50.0	57	(4.3)
Interest cost	5	2	157.0	8	(42.5)
PBT	12	243	(95.2)	357	(96.7)
Taxes	4	84	(95.8)	91	(96.1)
Effective tax rate (%)	30.1	34.7	(462bps)	25.5	458bps
APAT	8	159	(94.9)	266	(96.9)



STANDALONE QUARTERLY TRENDS




Source: Company, BOBCAPS Research




Source: Company, BOBCAPS Research

FIG 5 - REALISATIONS



Source: Company, BOBCAPS Research

FIG 6 - VOLUMES



Source: Company, BOBCAPS Research

Earnings call highlights

- MUNI had no sales in April whereas May saw minimal demand due to the lockdown. However, June saw much better traction followed by further improvement in July.
- Management expects Q2FY21 to recover to ~60% of YoY sales and is hopeful of normalisation in sales trend by Q4FY21. The company believes it will retrace to FY20 revenue levels in FY22.
- The automotive business has seen better traction than the footwear segment.
 MUNI believes auto segment demand will continue to recover faster than footwear till Diwali (i.e. mid-November).
- The company is now an approved vendor for Volkswagen India and will start supplies from Q3FY21, with potential annual sales of Rs 120mn-150mn.
- MUNI is also in talks with BMW for material supply and is awaiting approval.

MAYUR UNIQUOTERS



- Supply to Mercedes, South Africa, will begin in Q4FY21/Q1FY22.
- Product sampling is underway at the new PU plant and production will be ramped up from September to ~0.1mn mtr per month – this can yield monthly revenue of ~Rs 20mn.
- In India, ~90% of PU imports are from China. If the government introduces import curbs, as has been done in other sectors, the company will be a significant beneficiary.
- Recent cost control initiatives should provide some cushion to margins in a falling demand environment.



Valuation methodology

MUNI is the market leader in India's PVC synthetic leather industry and also caters to US auto OEMs – a market that no other domestic company has managed to penetrate. It has also entered the PU synthetic leather market which is primarily import-oriented, with the commencement of a plant in Madhya Pradesh in Jan'20.

We maintain estimates and roll over to a new Sep'21 TP of Rs 270 (earlier Rs 250), retaining our target one-year forward P/E of 15x. The stock has run up ~22% since **our last report on 30 June** – current valuations of 15.3x FY22E EPS leave limited upside, driving our rating downgrade from BUY to ADD.

FIG 7 - RELATIVE STOCK PERFORMANCE



Source: NSE

Key risks

- Failure to run the PU plant: Inability to run the newly commissioned PU plant will adversely affect growth prospects.
- Continued slowdown in end-user industries: A prolonged slowdown in key end-user industries of footwear and auto will adversely affect growth prospects.
- Volatility in raw material prices: A majority of MUNI's raw material is linked to crude prices. Any abnormal increase/decrease in crude prices can hurt the company's profitability.
- Prolonged Covid-19 outbreak: If pandemic fears prevail for a prolonged period of time, revenues will be adversely affected.



FINANCIALS

Income Statement

Y/E 31 Mar (Rs mn)	FY19A	FY20P	FY21E	FY22E	FY23E
Total revenue	5,913	5,280	3,685	5,617	6,261
EBITDA	1,292	1,039	551	1,107	1,295
Depreciation	(180)	(184)	(247)	(287)	(325)
EBIT	1,112	855	304	820	970
Net interest income/(expenses)	(9)	(17)	(20)	(10)	(8)
Other income/(expenses)	42	198	154	186	203
Exceptional items	0	0	0	0	0
EBT	1,145	1,036	438	995	1,164
Income taxes	(418)	(238)	(110)	(251)	(293)
Extraordinary items	169	0	0	0	0
Min. int./Inc. from associates	0	0	0	0	0
Reported net profit	896	798	328	744	871
Adjustments	(169)	0	0	0	0
Adjusted net profit	727	798	328	744	871

Balance Sheet

Y/E 31 Mar (Rs mn)	FY19A	FY20P	FY21E	FY22E	FY23E
Accounts payables	592	610	454	646	720
Other current liabilities	151	222	102	161	177
Provisions	30	76	18	28	31
Debt funds	217	261	200	100	70
Other liabilities	32	16	19	23	29
Equity capital	226	227	227	227	227
Reserves & surplus	4,953	5,547	5,776	6,298	6,907
Shareholders' fund	5,179	5,774	6,003	6,524	7,134
Total liabilities and equities	6,201	6,960	6,797	7,483	8,161
Cash and cash eq.	203	586	254	45	96
Accounts receivables	890	970	757	985	1,098
Inventories	1,229	1,351	989	1,339	1,492
Other current assets	337	359	252	308	343
Investments	1,870	1,652	2,450	2,500	2,900
Net fixed assets	1,242	1,644	1,697	1,910	1,835
CWIP	393	393	393	393	393
Intangible assets	38	3	3	3	3
Total assets	6,201	6,960	6,797	7,483	8,161



Cash Flows

Y/E 31 Mar (Rs mn)	FY19A	FY20P	FY21E	FY22E	FY23E
Net income + Depreciation	1,076	982	575	1,032	1,195
Interest expenses	9	17	20	10	8
Non-cash adjustments	0	0	0	0	0
Changes in working capital	(276)	(88)	350	(368)	(203)
Other operating cash flows	0	0	0	0	0
Cash flow from operations	809	911	945	674	1,001
Capital expenditures	(498)	(494)	(300)	(500)	(250)
Change in investments	(308)	218	(798)	(50)	(400)
Other investing cash flows	0	0	0	0	0
Cash flow from investing	(806)	(276)	(1,098)	(550)	(650)
Equities issued/Others	0	0	0	0	0
Debt raised/repaid	159	44	(61)	(100)	(30)
Interest expenses	(9)	(17)	(20)	(10)	(8)
Dividends paid	(177)	(178)	(98)	(223)	(261)
Other financing cash flows	(56)	(101)	0	0	0
Cash flow from financing	(83)	(252)	(180)	(333)	(300)
Changes in cash and cash eq.	(80)	384	(332)	(209)	51
Closing cash and cash eq.	203	586	254	45	96

Per Share

Y/E 31 Mar (Rs)	FY19A	FY20P	FY21E	FY22E	FY23E
Reported EPS	19.8	17.6	7.2	16.4	19.2
Adjusted EPS	16.0	17.6	7.2	16.4	19.2
Dividend per share	3.3	3.0	1.8	4.1	4.8
Book value per share	114.4	127.4	132.4	143.9	157.4

Valuations Ratios

Y/E 31 Mar (x)	FY19A	FY20P	FY21E	FY22E	FY23E
EV/Sales	1.7	1.8	2.6	1.6	1.4
EV/EBITDA	7.6	9.2	17.2	8.3	6.9
Adjusted P/E	15.7	14.3	34.8	15.3	13.1
P/BV	2.2	2.0	1.9	1.7	1.6

DuPont Analysis

Y/E 31 Mar (%)	FY19A	FY20P	FY21E	FY22E	FY23E
Tax burden (Net profit/PBT)	63.5	77.0	74.8	74.8	74.8
Interest burden (PBT/EBIT)	103.0	121.1	144.0	121.4	120.0
EBIT margin (EBIT/Revenue)	18.8	16.2	8.3	14.6	15.5
Asset turnover (Revenue/Avg TA)	102.6	80.2	53.6	78.7	80.0
Leverage (Avg TA/Avg Equity)	1.2	1.2	1.2	1.1	1.1
Adjusted ROAE	15.0	14.6	5.6	11.9	12.8

Source: Company, BOBCAPS Research | Note: TA = Total Assets

MAYUR UNIQUOTERS



Ratio Analysis

Y/E 31 Mar	FY19A	FY20P	FY21E	FY22E	FY23E
YoY growth (%)					
Revenue	3.7	(10.7)	(30.2)	52.4	11.5
EBITDA	(13.9)	(19.6)	(46.9)	100.7	17.0
Adjusted EPS	(19.7)	9.8	(58.9)	127.2	17.0
Profitability & Return ratios (%)					
EBITDA margin	21.9	19.7	15.0	19.7	20.7
EBIT margin	18.8	16.2	8.3	14.6	15.5
Adjusted profit margin	12.3	15.1	8.9	13.3	13.9
Adjusted ROAE	15.0	14.6	5.6	11.9	12.8
ROCE	14.2	11.5	3.7	9.6	10.5
Working capital days (days)					
Receivables	59	64	86	57	61
Inventory	112	153	196	126	139
Payables	47	52	62	45	50
Ratios (x)					
Gross asset turnover	3.5	2.6	1.5	2.0	1.9
Current ratio	3.1	3.2	3.4	3.1	3.2
Net interest coverage ratio	128.4	49.1	15.2	82.0	115.5
Adjusted debt/equity	0.0	(0.1)	0.0	0.0	0.0



Disclaimer

Recommendations and Absolute returns (%) over 12 months

BUY - Expected return >+15%


ADD - Expected return from >+5% to +15%

REDUCE - Expected return from -5% to +5%

SELL - Expected return <-5%

Note: Recommendation structure changed with effect from 1 January 2018 (Hold rating discontinued and replaced by Add / Reduce)

RATINGS AND TARGET PRICE (3-YEAR HISTORY): MAYUR UNIQUOTERS (MUNI IN)



B - Buy, A - Add, R - Reduce, S - Sell

Rating distribution

As of 31 July 2020, out of 96 rated stocks in the BOB Capital Markets Limited (BOBCAPS) coverage universe, 46 have BUY ratings, 20 have ADD ratings, 11 are rated REDUCE and 19 are rated SELL. None of these companies have been investment banking clients in the last 12 months.

Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOBCAPS.

General disclaimers

BOBCAPS is engaged in the business of Institutional Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS has obtained registration as a Research Entity under SEBI (Research Analysts) Regulations, 2014, having registration No.: INH000000040 valid till 03 February 2020. BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations

MAYUR UNIQUOTERS



expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities —that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may act as market makers or assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

In the US, this material is only for Qualified Institutional Buyers as defined under rule 144(a) of the Securities Act, 1933. No part of this document may be distributed in Canada or used by private customers in the United Kingdom.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company in the past 12 months. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

 ${\sf BOBCAPS} \ or \ its \ research \ analyst(s) \ is \ not \ engaged \ in \ any \ market \ making \ activities \ for \ the \ subject \ company.$

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.